The combination of fluoxetine and short-term low-dose olanzapine in patients with comorbid anxiety and depression

Effectiveness and safety of the combination of fluoxetine and short-term low-dose olanzapine in patients with comorbid anxiety and depression

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-11001748

Enrollment

Unknown

Registered

2011-11-29

Start date

2009-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

comorbid anxiety and depression

Interventions

Experimental:fluoxetine and olanzapine

control:fluoxetine

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: patients fulfilling the following eligibility criteria were recruited in our study: 1. meet Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), anxiety and depressive disorders criteria; 2. achieve a Hamilton Anxiety Rating Scale (HAM-A, 14 items edition) score of 14 or higher, as well as a Hamilton Depression Rating Scale (HDRS, 24 items edition) score of 24 or higher; 3. do not receive any antidepressant treatment.

Exclusion criteria

Exclusion criteria: The following patients were excluded: 1. pregnant or breast-feeding; 2. with serious or unstable nonpsychiatric diseases; 3. a history of epilepsy; 4. leucopenia or neutropenia by any reasons.

Design outcomes

Primary

Measure	Time frame
HAM-A;HDRS;TESS;	—

Countries

China

Contacts

Public ContactZhonglin Liu

zhonglinliu@126.com+86 13719438236

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026